D. Miller

S. Arridge, G. Parker, P. Tofts, 2000, IWISPA 2000. Proceedings of the First International Workshop on Image and Signal Processing and Analysis. in conjunction with 22nd International Conference on Information Technology Interfaces. (IEEE.

Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results

Altmann, D. MacManus, K. Schmierer, 2016 .

Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis

Vm Anderson, David H. Miller, Jeremy Chataway, 2008, Multiple sclerosis.

Primary progressive multiple sclerosis diagnostic criteria: a reappraisal

A. Thompson, F. Barkhof, M. Rovaris, 2009, Multiple sclerosis.

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta

D. Miller, P. Rudge, G. Giovannoni, 2008, Multiple sclerosis.

The role of MRI as a surrogate outcome measure in multiple sclerosis

F. Barkhof, D. Miller, H. McFarland, 2002 .

MATTERS ARISING

G. Barker, D. Miller, C. Davie, 1995 .

Correlation of Somatosensory Evoked Potential Abnormalities with Brain and Cervical Cord Magnetic Resonance Imaging in Multiple Sclerosis

R. Kakigi, D. Miller, G. Boulay, 1991 .

Automatic sodium maps reconstruction using PatchMatch algorithm for phantom detection

Sebastien Ourselin, Dh Miller, Cam Wheeler-Kingshott, 2016 .

Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis

F. Barkhof, M. Filippi, D. Miller, 1997, Multiple sclerosis.

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis

F. Barkhof, C. Polman, D. Miller, 1996, Multiple sclerosis.

Lesion enhancement diminishes with time in primary progressive multiple sclerosis

O. Ciccarelli, A. Thompson, D. Altmann, 2010, Multiple sclerosis.

Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis

D. Miller, D. Garway-Heath, A. Thompson, 2007, Multiple sclerosis.

An investigation of brain neurite density and dispersion in multiple sclerosis using single shell diffusion imaging.

Cam Wheeler-Kingshott, Declan T. Chard, Olga Ciccarelli, 2014 .

Effects of BG-12 on Magnetic Resonance Imaging (MRI) Endpoints in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Data From the Phase 3 CONFIRM Study (S11.001)

D. Miller, M. Hutchinson, E. Havrdová, 2012 .

Quantitative techniques for lesion load measurement in multiple sclerosis: an assessment of the global threshold technique after non uniformity and histogram matching corrections

G. Barker, D. Miller, I. Moseley, 1998, European journal of neurology.

Magnetization Transfer Ratio Imaging Is Feasible in Large Multicenter MS Trials

Sridar Narayanan, Mishkin Derakhshan, Katherine Dawson, 2010 .

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

D. Miller, H. McFarland, J. Petkau, 2008, Multiple sclerosis.

Early Initiation of Interferon Beta-1b after a First Clinical Event Suggestive of Multiple Sclerosis: Clinical Outcomes and Use of Disease-Modifying Therapy from the BENEFIT Extension Study (PD5.002)

F. Barkhof, X. Montalban, L. Kappos, 2012 .

Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis

A. Thompson, M. Cercignani, K. Schmierer, 2009, Multiple sclerosis.

Impact of early interferon beta-1b treatment on disease evolution over five years in patients with a first event suggestive of multiple sclerosis

F. Barkhof, X. Montalban, L. Kappos, 2008 .

Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis

Limmroth, D. MacManus, L. Kappos, 2007 .

BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis

Limmroth, D. MacManus, L. Kappos, 2006 .

Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes

D. Altmann, D. Miller, P. Tofts, 2007, Multiple sclerosis.

Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

Viglietta, D. Miller, M. Hutchinson, 2012 .

Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis) study

Viglietta, D. Miller, M. Hutchinson, 2012 .

Quantification of spinal cord atrophy from magnetic resonance images via a B‐spline active surface model

G J Barker, S R Arridge, O Coulon, 2002, Magnetic resonance in medicine.

Triple dose gadolinium enhanced MRI of the brain and spinal cord in early relapsing remitting multiple sclerosis is predictive of future relapses

D. Miller, D. Chard, W. Rashid, 2002 .

The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study

L. Kappos, C. Polman, D. Miller, 2006 .

Disability and T2 MRI abnormalities: A 20 year follow-up of patients with relapse onset of multiple sclerosis

Altmann, D. Miller, K. Miszkiel, 2007 .

The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study

Ludwig Kappos, Tarek A. Yousry, Dh Miller, 2008 .

OPL100 The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS

Wynn, L. Kappos, C. Polman, 2005, Journal of the Neurological Sciences.

A double-blind, placebo-controlled trial of interferon beta-1b in secondary progressive multiple sclerosis: Magnetic resonance imaging results

G. Barker, D. MacManus, D. Miller, 1998 .

Texture analysis of magnetization transfer maps from patients with clinically isolated syndrome and multiple sclerosis

A J Thompson, D. Miller, D. Tozer, 2009, Journal of magnetic resonance imaging : JMRI.

Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS)

Ludwig Kappos, Xavier Montalban, Dh Miller, 2015 .

Spinal cord atrophy and disability in multiple sclerosis: a longitudinal study

Dh Miller, Aj Thompson, Gjm Parker, 1998 .

Different white matter lesion characteristics correlate with distinct grey matter abnormalities on magnetic resonance imaging in secondary progressive multiple sclerosis

J Chataway, D. Altmann, D. Miller, 2009, Multiple sclerosis.

H-1 magnetic resonance spectroscopy of normal-appearing white matter in primary progressive multiple sclerosis

D. MacManus, G. Parker, D. Miller, 1998 .

Interferon-beta-1b reduces development of T1 black holes on MRI in secondary progressive multiple sclerosis

Ludwig Kappos, Tarek A. Yousry, Massimo Filippi, 2000 .

MRI monitoring of cerebral atrophy during a placebo-controlled trial of interferon-beta-1b in secondary progressive multiple sclerosis

F. Barkhof, M. Filippi, C. Pozzilli, 2000 .

Urinary neopterin and nitric oxide metabolites as markers of interferon β-1a activity in primary progressive multiple sclerosis

D. Miller, D. Miller, G. Giovannoni, 2010, Multiple sclerosis.

Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination

D. Miller, W. Mcdonald, M. Sailer, 1999, Neurology.

The predictive value of brain lesion load in determining brain atrophy in multiple sclerosis: 14 year follow up data following first presentation with a clinically isolated syndrome

Dh Miller, Aj Thompson, Declan T. Chard, 2002 .

Wellington , New Zealand . to multiple sclerosis in Ethnic and HLA patterns related

D. Miller, R. Hornabrook, J. Dagger, 2022 .

Highresolution magnetic resonance imaging of theanterior visual pathway inpatients withoptic neuropathies using fast spinechoandphased arraylocal coils

M. Sanders, A. Gass, D. Miller, 1995 .

Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon‐β

D. Miller, W. Mcdonald, A. J. Thompson, 1994, Annals of neurology.

The British Isles survey of multiple sclerosis in twins

D. Miller, N. Wood, J. Thorpe, 1994, Neurology.

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

D. MacManus, A. Chaudhuri, D. Miller, 1999, Neurology.

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial

F. Barkhof, C. Polman, D. Miller, 1997, Neurology.

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

A. Thompson, F. Barkhof, D. Miller, 1991, Journal of neurology, neurosurgery, and psychiatry.

Escalating immunotherapy of multiple sclerosis

A. Gass, L. Kappos, S. Schmidt, 2004, Journal of Neurology.

Psychiatric and neurological manifestations in systemic lupus erythematosus.

M. Ron, D. Miller, M. Walport, 1988, The Quarterly journal of medicine.

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

F. Barkhof, M. Rovaris, M. Filippi, 2001, Journal of neurology, neurosurgery, and psychiatry.

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

D. Miller, S. Cepok, B. Hemmer, 2009, Neurology.

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

L. Kappos, F. D. Lublin, D. G. MacManus, 2007, Neurology.

Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data

F. Barkhof, M. Rovaris, M. Filippi, 2005, Neurology.

A longitudinal study of cognition in primary progressive multiple sclerosis.

A. Thompson, M. Filippi, X. Montalban, 2005, Brain : a journal of neurology.

Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis

O. Ciccarelli, D. Miller, C. Wheeler-Kingshott, 2014, Journal of Neurology, Neurosurgery & Psychiatry.

Diagnostic criteria for primary progressive multiple sclerosis: A position paper

A J Thompson, F Barkhof, M Filippi, 2000, Annals of neurology.

Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates.

A. Thompson, M. Filippi, D. Miller, 1999, Brain : a journal of neurology.

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

X. Montalban, L. Kappos, C. Polman, 2012, Multiple sclerosis.

Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis

A. Thompson, D. Miller, N. Losseff, 2001, Journal of Neurology.

Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b

C. Pozzilli, L. Kappos, C. Polman, 2003, Neurology.

The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study.

G J Barker, M R Symms, A J Thompson, 2000, Brain : a journal of neurology.

Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis

W. I. McDonald, B. E. Kendall, J. W. Thorpe, 1996, Neurology.

Intravenous immunoglobulin versus plasma exchange in Guillain‐Bard syndrome

D. Miller, R. Howard, N. Hirsch, 1993, Neurology.

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

G Cutter, D. Dougherty, D. Miller, 2001, Neurology.

Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.

P Kapeller, A J Thompson, A. Thompson, 2002, Brain : a journal of neurology.

Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis.

D. Miller, D. Kidd, G. Giovannoni, 1997, Brain : a journal of neurology.

Primary progressive multiple sclerosis: a 5-year clinical and MR study.

A. Thompson, D. Miller, D. Miller, 2003, Brain : a journal of neurology.

Magnetic resonance imaging in clinical practice

Dh Miller, Aj Thompson, Aj Thompson, 1992 .

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

G J Barker, A J Thompson, F Barkhof, 2000, Brain : a journal of neurology.

Progressive neuronal degeneration of childhood with liver disease (Alpers' disease) presenting in young adults.

S. Smith, B. Harding, F. Scaravilli, 1995, Journal of neurology, neurosurgery, and psychiatry.

Magnetic resonance imaging of the central nervous system in Behçet's disease.

D. Miller, W. Mcdonald, P. Rudge, 1993, European neurology.

The incidence and significance of anti-natalizumab antibodies

D. Miller, L. Kappos, C. Polman, 2007, Neurology.

Guidelines for using proton MR spectroscopy in multicenter clinical MS studies

P M Matthews, M Filippi, P. Matthews, 2007, Neurology.

The optic nerve sheath on MRI in acute optic neuritis

G. T. Plant, G. Plant, D. Miller, 2005, Neuroradiology.

Longitudinal study of soluble adhesion molecules in multiple sclerosis

A. Thompson, D. Miller, D. Miller, 1997, Neurology.

Use of magnetic-resonance spectroscopy to investigate disability in multiple-sclerosis

G. Barker, D. Miller, C. Davie, 1994 .

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis

A. Thompson, F. Barkhof, M. Filippi, 2009, Neurology.

Lymphocyte-endothelial cell interactions in multiple sclerosis: disease specificity and relationship to circulating tumour necrosis factor-α and soluble adhesion molecules

D. Miller, R. Hughes, D. Kidd, 1997, Multiple sclerosis.

Application of multi-shell NODDI in Multiple Sclerosis

Dh Miller, Torben Schneider, Hui Zhang, 2014 .

Management of acute optic neuritis

D. Miller, G. Plant, S. Hickman, 2002, The Lancet.

Detection of grey matter lesions in multiple sclerosis using magnetic resonance imaging: preliminary results of a comparison of phase-sensitive inversion recovery with dual inversion recovery imaging at 3T

Dh Miller, Cam Wheeler-Kingshott, Xavier Golay, 2010 .

The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study

A J Thompson, G J M Parker, O Ciccarelli, 2003, Journal of neurology, neurosurgery, and psychiatry.

Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study

A J Thompson, A. Thompson, D. Altmann, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of Interferon beta-1b in patients with Secondary Progressive Multiple Sclerosis

C. Polman, D. Miller, F. Dahlke, 2005, Journal of Neurology.

Early pericalcarine atrophy in acute optic neuritis is associated with conversion to multiple sclerosis

O. Ciccarelli, A. Thompson, D. Miller, 2011, Journal of Neurology, Neurosurgery & Psychiatry.

A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis

A. Toosy, K. Schmierer, D. Altmann, 2012 .